Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03245736 · ClinicalTrials.gov registry record · Phase 2
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
A Phase 2 study of Prostate Cancer and Bladder Cancer, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 4
- Study locations
NCT03245736 is a Phase 2 study of Prostate Cancer and Bladder Cancer that has completed, run by Seagen. The registered enrollment target is 5 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT03245736, a Phase 2 study of Prostate Cancer and Bladder Cancer, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
Conditions Studied
Interventions
- DRUG Tisotumab Vedotin
Study Locations (4)
Other
- Johann de Bono - Chelsea
- Beatson Cancer Centre - Glasgow
- Fiona Thistlethwaite - Manchester
Florida
- Brian Slomovitz - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-08-23 |
| Est. Completion | 2019-01-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03245736
The ClinicalTrials.gov registry entry for NCT03245736 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tisotumab Vedotin is the first listed.
NCT03245736 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Other, Florida.
Frequently Asked Questions
What is clinical trial NCT03245736 about?
NCT03245736 is a clinical study titled "Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.". The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
What is the current status of trial NCT03245736?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-08-23. Estimated completion is 2019-01-10.
What conditions does trial NCT03245736 study?
This clinical trial studies the following conditions: Prostate Cancer, Bladder Cancer, Squamous Cell Carcinoma of the Head and Neck, Esophagus Cancer, Ovary Cancer.
What interventions are being tested in trial NCT03245736?
The interventions under investigation include: Tisotumab Vedotin (DRUG).
Who is sponsoring clinical trial NCT03245736?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03245736 being conducted?
This trial has 4 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.